$28.32
-0.11[-0.39%]
At close: Apr 18
$28.32
0[0.00%]
After Hours: 4:00PM EDT
Immunovant
(NASDAQ:IMVT)Immunovant Stock (NASDAQ:IMVT), Analyst Ratings, Price Targets, Predictions
Immunovant Inc has a consensus price target of $39, established from looking at the 59 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Truist Securities, and Goldman Sachs on March 28, 2024, March 25, 2024, and March 13, 2024. With an average price target of $49.33 between Oppenheimer, Truist Securities, and Goldman Sachs, there's an implied 74.20% upside for Immunovant Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Truist Securities
Goldman Sachs
JP Morgan
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Immunovant
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | IMVT | Buy Now | Immunovant | $28.32 | 76.55% | Oppenheimer | Leland Gershell | → $50 | Initiates | → Outperform | Get Alert |
| 03/25/2024 | IMVT | Buy Now | Immunovant | $28.32 | 69.49% | Truist Securities | Robyn Karnauskas | → $48 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | IMVT | Buy Now | Immunovant | $28.32 | 76.55% | Goldman Sachs | Corinne Johnson | → $50 | Initiates | → Buy | Get Alert |
| 02/20/2024 | IMVT | Buy Now | Immunovant | $28.32 | 80.08% | JP Morgan | Brian Cheng | → $51 | Initiates | → Overweight | Get Alert |
| 02/15/2024 | IMVT | Buy Now | Immunovant | $28.32 | 94.21% | Wolfe Research | Andy Chen | → $55 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | IMVT | Buy Now | Immunovant | $28.32 | 80.08% | B of A Securities | Jason Gerberry | $49 → $51 | Maintains | Buy | Get Alert |
| 12/21/2023 | IMVT | Buy Now | Immunovant | $28.32 | 80.08% | HC Wainwright & Co. | Douglas Tsao | $47 → $51 | Maintains | Buy | Get Alert |
| 12/12/2023 | IMVT | Buy Now | Immunovant | $28.32 | 76.55% | Deutsche Bank | Neena Bitritto-Garg | → $50 | Initiates | → Buy | Get Alert |
| 12/01/2023 | IMVT | Buy Now | Immunovant | $28.32 | 97.74% | UBS | Colin Bristow | $55 → $56 | Maintains | Buy | Get Alert |
| 11/15/2023 | IMVT | Buy Now | Immunovant | $28.32 | 69.49% | Truist Securities | Robyn Karnauskas | $30 → $48 | Maintains | Buy | Get Alert |
| 10/24/2023 | IMVT | Buy Now | Immunovant | $28.32 | 101.27% | Piper Sandler | Yasmeen Rahimi | $28 → $57 | Maintains | Overweight | Get Alert |
| 10/24/2023 | IMVT | Buy Now | Immunovant | $28.32 | 65.96% | HC Wainwright & Co. | Douglas Tsao | $29 → $47 | Maintains | Buy | Get Alert |
| 10/16/2023 | IMVT | Buy Now | Immunovant | $28.32 | 58.9% | Cantor Fitzgerald | Louise Chen | $30 → $45 | Maintains | Overweight | Get Alert |
| 10/13/2023 | IMVT | Buy Now | Immunovant | $28.32 | 94.21% | UBS | Colin Bristow | $18 → $55 | Upgrade | Neutral → Buy | Get Alert |
| 10/09/2023 | IMVT | Buy Now | Immunovant | $28.32 | 5.93% | Cantor Fitzgerald | Louise Chen | → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | IMVT | Buy Now | Immunovant | $28.32 | 69.49% | Wells Fargo | Derek Archila | $33 → $48 | Maintains | Overweight | Get Alert |
| 09/27/2023 | IMVT | Buy Now | Immunovant | $28.32 | 76.55% | Citigroup | Samantha Semenkow | $33 → $50 | Maintains | Buy | Get Alert |
| 09/27/2023 | IMVT | Buy Now | Immunovant | $28.32 | 41.24% | Raymond James | Danielle Brill | → $40 | Upgrade | Market Perform → Outperform | Get Alert |
| 09/26/2023 | IMVT | Buy Now | Immunovant | $28.32 | 5.93% | Truist Securities | Robyn Karnauskas | → $30 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Immunovant (IMVT)?
The latest price target for Immunovant (NASDAQ: IMVT) was reported by Oppenheimer on March 28, 2024. The analyst firm set a price target for $50.00 expecting IMVT to rise to within 12 months (a possible 76.55% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunovant (IMVT)?
The latest analyst rating for Immunovant (NASDAQ: IMVT) was provided by Oppenheimer, and Immunovant initiated their outperform rating.
When was the last upgrade for Immunovant (IMVT)?
The last upgrade for Immunovant Inc happened on October 13, 2023 when UBS raised their price target to $55. UBS previously had a neutral for Immunovant Inc.
When was the last downgrade for Immunovant (IMVT)?
The last downgrade for Immunovant Inc happened on September 26, 2022 when UBS changed their price target from $7 to $5 for Immunovant Inc.
When is the next analyst rating going to be posted or updated for Immunovant (IMVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunovant, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunovant was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating Immunovant (IMVT) correct?
While ratings are subjective and will change, the latest Immunovant (IMVT) rating was a initiated with a price target of $0.00 to $50.00. The current price Immunovant (IMVT) is trading at is $28.32, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.